The Leeds Teaching Hospitals NHS Trust


Phase 3 multi-centre, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-COVID)



This is a randomised controlled trial, looking at the effect of a canakinumab on those with significant Covid-19 induced acquired pneumonia.  Canakinumab is a human monoclonal antibody, which has been used to treat inflammatory conditions such as rheumatoid arthritis. 


This is a study which is considered a national priority.


Participants will be randomised into one of two arms: 

  • Canakinumab plus standard care
  • Placebo plus standard care 

Data will be collected daily while in hospital and then followed up 2 months and 4 months later.

Who can participate?

Patients will be eligible if they are

  1. Hospitalised with Symptoms
  2. Confirmation of SARS-CoV-2 infection by PCR
  3. Pneumonia evidence by chest x-ray or CT scan with pulmonary infiltrates
  4. SpO2 ≤ 93%
  5. Fever of ≥38°C/100.4°F within 48 hours prior to randomisation

Exclusion criteria

  • Known sensitivity to canakinumab
  • Those on mechanical ventilation
  • Pregnant or breast feeding
  • Suspected active bacterial, fungal, viral and parasitic infection with the exception of Covid-19